Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Filid Tecnologia Farmacêutica Ltda (Me) currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a single distinct art unit, indicating a focused technical scope for the company's current pending matters. The concentration in this art unit suggests that the subject matter falls within a specific niche of the sector. This focus allows for a specialized prosecution approach within the Biotechnology & Pharmaceuticals field.
The prosecution of this portfolio is handled by a sole distinct examiner. The busiest examiner for this portfolio is COHEN, MICHAEL P, who is currently responsible for 1 pending office action. For a practitioner, this means that understanding the specific examination style of the assigned examiner is critical, as this individual manages the entirety of the pending workload. This level of concentration simplifies the coordination of prosecution strategy but increases the impact of a single examiner's perspective. The outcome of the pending matter will be determined by the interaction with this examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COHEN, MICHAEL P | 1 | 58.7% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667477 | Method for Preparing an Intramammary Teat Sealing Composition and Sealing Composition Obtained By Such Process | COHEN, MICHAEL P | 82d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667477 | Method for Preparing an Intramammary Teat Sealing Composition and Sealing Composition Obtained By Such Process | COHEN, MICHAEL P | 82d |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667477 | Method for Preparing an Intramammary Teat Sealing Composition and Sealing Composition Obtained By Such Process | COHEN, MICHAEL P | 1612 | §103§112 | Non-Final OA | 82d | Pending | May 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial